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Abstract
Background: Cerebral malaria (CM) is a lethal complication of Plasmodium falciparum infections. In the
Plasmodium berghei ANKA (PbA) murine model, CM is associated with marked brain inflammation, increased
expression of endothelial cell adhesion molecules and leukocyte and platelet accumulation in brain vessels, causing
vascular occlusion and decreased blood flow, damaging the endothelium and leading to blood-brain barrier
breakdown, leakage and hemorrhages. Exogenous nitric oxide (NO) administration largely prevents the syndrome.
Here we evaluated whether the mechanism of action of NO in preventing murine CM is related to its anti-
inflammatory properties and to protection of the endothelium.
Methods: C57Bl/6 mice infected with PbA were treated twice a day with saline or dipropylenetriamineNONOate
(DPTA-NO). Endothelial cell adhesion molecule (ICAM-1, VCAM, E- and P-selectin) expression in brain tissue on day
6 of infection was assessed in both groups by western blot. For intravital microscopy studies, DPTA-NO-treated and
saline-treated mice with a previously implanted closed cranial window were injected with albumin-FITC, anti-CD45-
TxR and anti-CD41-FITC antibodies on day 6 of infection for quantification of albumin leakage, leukocyte and
platelet adherence in pial vessels.
Results: PbA-infected mice treated with the NO-donor DPTA-NO showed decreased expression of ICAM-1 and
P-selectin, but not VCAM-1, in the brain, compared to saline-treated mice. DPTA-NO treatment also decreased the
number of adherent leukocytes and platelets in pial vessels, particularly in venules 30-50 μm in diameter,
decreased inflammatory vascular resistance and prevented the occurrence of arteriolar and venular albumin
leakage observed in saline-treated PbA-infected mice, as assessed by intravital microscopy.
Conclusions: These results indicate that the protective effect of exogenous NO on murine CM is associated with
decreased brain vascular expression of inflammatory markers resulting in attenuated endothelial junction damage
and facilitating blood flow.
Introduction
Cerebral malaria (CM), a complication of malaria infec-
tion by Plasmodium falciparum, is a leading cause of
mortality and neurological impairment in endemic
areas, with an estimated 1 million deaths every year [1].
In the murine model of CM by P. berghei ANKA (PbA),
the neurological syndrome is associated with several
indicators of severe vasculopathy and endothelial dys-
function, whose pathogenesis is complex and involves a
systemic inflammatory response with activation of CD4+
and CD8+ T cells, macrophages, platelets, release of sev-
eral pro-inflammatory cytokines such as IFN-g, TNF-a
and LTA [2-8] as well as depletion of nitric oxide (NO)
[9] and increased expression of endothelin-1 and other
vasoactive elements [10,11]. These events cause the vas-
cular beds in the brain and other organs to upregulate
the expression of a number of endothelial cell adhesion
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molecules (eCAMs), including ICAM-1, VCAM-1 and
P-selectin [12]. The activated endothelium facilitates the
recruitment of different cell types, including monocytes,
lymphocytes, platelets and pRBCs, which interact with
the eCAMs, roll and adhere, accumulating, and ulti-
mately plugging the brain vessels and causing blood
flow disturbances or even complete vascular blockades
[13]. Interaction with adherent cells can also result in
endothelial cell dysfunction and damage through direct
contact or the release of active compounds such as cyto-
kines and perforin, leading to BBB disruption, with leak-
age of plasma contents into the brain parenchyma
which can induce neurotoxicity or contribute to brain
edema [14-16]. A damaged vessel may eventually rup-
ture causing the disseminated hemorrhages commonly
observed in murine CM [17,18].
Endothelial dysfunction by different mechanisms such
as NO depletion can contribute to vascular inflamma-
tion. It has been shown that low NO bioavailability or
NO inhibition can induce the expression of eCAMs
[19-21], platelet activation and adhesion to endothelial
cells [22,23] and increase baseline leukocyte rolling and
adherence [24,25], and administration of NO donors
inhibits endothelial activation [26]. Low NO bioavailabil-
ity is a major player in vascular inflammation commonly
observed in hemolytic syndromes such as sickle cell cri-
sis, in which acellular hemoglobin acts as a strong NO
scavenger [27]. Murine CM is associated with low NO
bioavailability due largely to NO-scavenging by plasma
hemoglobin, and exogenous supplementation of NO to
PbA-infected mice largely prevents CM [9]. We have
recently shown that this protection is associated with
improved cerebral microcirculatory function, as NO
supplementation prevented pial vasoconstriction and
attenuated the decrease in pial blood flow in PbA-
infected mice [18].
In the present study, we show that NO supplementa-
tion acts by decreasing eCAM expression in the brain
leading to decreased adherence of leukocytes and plate-
lets in pial vessels and preventing vascular leakage in
arterioles and venules.
Methods
Parasite, infection and NO-donor treatment
Animal handling and care followed the NIH Guide for
Care and Use of Laboratory Animals. All protocols were
approved by the La Jolla Bioengineering Institutional
Animal Care and Use Committee. Eight to 12-week old
C57Bl/6 (Jackson Laboratories, ME) were inoculated
intraperitoneally (IP) with 1 × 106 Plasmodium berghei
ANKA parasites expressing the green fluorescent pro-
tein (PbA-GFP, a donation from the Malaria Research
and Reference Reagent Resource Center - MR4, Mana-
ssas, VA; deposited by CJ Janse and AP Waters; MR4
number: MRA-865). Parasitemia, body weight, rectal
temperature and clinical status (using six simple tests
adapted from the SHIRPA protocol, as previously
described [18], were monitored daily from day 4. Parasi-
temia was checked by flow cytometry by detecting the
number of fluorescent GFP-expressing pRBCs in rela-
tion to 10,000 RBCs. CM was defined as the presenta-
tion of one or more of the following clinical signs of
neurological involvement: ataxia, limb paralysis, poor
righting reflex, seizures, roll-over, coma. PbA-infected
mice were treated with either saline or dipropylenetria-
mine NONOate (DPTA-NO, Cayman Chemical, Ann
Arbor, MI) 1 mg/mouse, intraperitoneally (IP), twice a
day starting on day 0 of infection.
Brain endothelial cell adhesion molecule expression
quantification
On day 6 of infection, saline-treated and DPTA-NO-
treated PbA-infected mice, as well as uninfected control
mice, were euthanized with 100 mg/kg of euthasol IP,
perfused with saline and the brains collected and frozen
at -80°C until processing. Brains were defrosted and
homogenized in lysis buffer (50 mM Tris pH7.5, 125
mM NaCl, 60 mM octylglucoside, 2 mM sodium vana-
date and protease inhibitor cocktail tablets (Complete,
Roche), on ice for 30 min than centrifuged at 14.000 g
for 20 min, the supernatant was diluted and proteins
were resolved by sodium dodecyl-sulphate polyacryla-
mide gel electrophoresis and then transferred onto
nitrocellulose membranes (Milipore). Membranes were
blocked and probed with antibodies to intercellular cell
adhesion molecule-1 (ICAM-1), vascular cell adhesion
molecule-1 (VCAM-1), P-selectin or E-selectin (all from
BD Biosciences). Detection was performed with anti-IgG
secondary antibodies conjugated to peroxidase and reac-
tion was developed with Super Signal West Pico Chemi-
luminescence Substrate (Thermo Scientific). After
development, antibodies were unbound using Restore
Western Blot Stripping buffer (Thermo Scientific), re-
incubated with antibodies to GAPDH (V-18) (Santa
Cruz) and reaction was developed by chemilumines-
cence. The band intensities were determined after scan-
ning the radiographic films and image analysis using
ImageJ (NIH) software, and eCAM expression was
normalized in relation to GAPDH expression.
Quantification of brain leukocyte and platelet adherence
and vascular leakage using intravital microscopy
The closed cranial window model was used as pre-
viously described [13,28]. After the implantation of the
cranial window, mice rested for 2-4 weeks before start-
ing the experiment. On the day before infection, a
panoramic picture of the vascular network under the
window was taken and, with the mouse under light
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isoflurane anesthesia, the pial vessels were checked in
the intravital microscope and 12 arterioles and venules
were randomly selected and marked in the panoramic
picture, and diameters measured using an image shear
device (Image Shear, Vista Electronics, San Diego, CA).
Mice were inoculated with PbA the next day, followed
up and treated with either saline or DPTA-NO as
described above. On day 6 of infection, a cocktail con-
taining albumin-FITC (Sigma, St Louis, MO; 50 μg),
anti-CD45-TxR antibodies (CalTag, Carlsbad, CA; 4 μg)
and anti-CD41-FITC antibodies (CalTag, Carlsbad, CA;
4 μg) was intravenously infused through the tail vein
(final volume: 75 μL). The mouse was then lightly
anesthetized with isoflurane (4% for induction, 1-2% for
maintenance) and put on a stereotaxic frame with the
head gently held with ear bars. A panoramic picture of
the vessels under the window was taken and the mouse
was transferred to the intravital microscope stage. Body
temperature, measured pre-anesthesia, was maintained
with a heating pad. Using water-immersion objectives
(20X), blood vessel images were captured (COHU 4815,
San Diego, CA) and recorded on video-tape. Diameter
measurements of 6-10 pial venules and 2-6 pial arter-
ioles previously selected as described above were per-
formed in each animal. Fifteen minutes after injection of
the fluorescent-labeled markers, green fluorescence
(518 nm) emitted by albumin-FITC, GFP (PbA pRBC)
and anti-CD41-FITC antibodies (platelets) was captured
using an ALPHA Vivid: XF100-2 (Omega Optical, Brat-
tleboro, VT), and red fluorescence (615 nm) emitted by
anti-CD45-TxR antibodies was exited and captured with
a Vivid Standard: XF42. Adherence was defined as cells
remaining static for 30 seconds. For each selected vessel,
leukocytes and platelets were quantified in a 100 μm-
long section. The pre-selection of vessels on day 0 to
perform the measurements was intended to avoid bias
in the quantifications, as different vessels may be hetero-
geneously affected by leukocyte and platelet adherence.
Vascular leakage was measured by quantifying the fluor-
escence emitted by albumin-FITC (Molecular Probes,
Eugene, OR) inside the vessel and in the surrounding
tissue, using ALPHA Vivid: XF100-2 (Exciter: XF1073;
Dichroic: XF2010; Emitter: XF3084, Omega Filters Brat-
tleboro, VT). The albumin-FITC was injected into the
tail vein and 15 min after infusion the fluorescence
emission signals were recorded using a photomultiplier
(Hamamatsu R928, Tokyo, Japan). Results of leakage are
expressed as the ratio of albumin-FITC-derived fluores-
cence intensity between the tissue and the vessel. Higher
ratios correspond to higher leakage. Inflammation
effects on vascular resistance were calculated by mathe-
matically using Darcy’s law and Hagen-Poiseuille equa-
tion relative to without inflammation. These estimations
were calculated by each microvessel using the ratio
between the microvessel with the volumes occupied by
adhered leukocytes relative to without leukocytes and
approximating the pressure drop through a non-variable
length cylindrical pipe as a function of the diameter to
the power of four (area square).
Statistical analysis
Statistical analyses were performed using analysis of var-
iance (ANOVA) with Dunnett’s post-hoc analysis to
compare eCAM expression, leukocyte and platelet
adherence and vascular leakage in uninfected, saline-
treated and DPTA-NO-treated PbA-infected mice. Cor-
relations were established using the Spearmann rank
test. All statistics were performed using the Graphpad
Prism software (GraphPad Software Inc., La Jolla, CA).
A p value < 0.05 was considered significant.
Results
DPTA-NO treatment decreases ICAM-1 and P-selectin, but
not VCAM-1, expression in the brain of PbA-infected mice
In the eCAM expression studies, 79% of the saline-
treated mice (n = 14) showed clinical signs of CM on
day 6 of infection, against 29% of the DPTA-NO-trea-
ted mice (n = 14). All mice were euthanized regardless
of CM expression and brains were collected. The
course of parasitemia was similar in both groups (sal-
ine: 10.8 ± 0.58%; DPTA-NO: 10.2 ± 0.65%, day 6 of
infection). Saline-treated PbA-infected mice showed
increased expression of ICAM-1, VCAM-1 and P-selec-
tin, but not E-selectin (Figure 1). ICAM-1 expression
was increased nearly 10-fold, whereas VCAM-1 and P-
selectin expression was increased about two-fold in
relation to uninfected controls. DPTA-NO treatment
caused significant reductions in ICAM-1 and P-selectin
expression, but did not significantly modify VCAM-1
expression (Figure 1).
DPTA-NO treatment decreases leukocyte and platelet
sequestration in the brain
Leukocyte/platelet adherence and albumin-FITC leakage
were evaluated in pial arterioles and venules ranging
from 20 to 50 μm in diameter using intravital micro-
scopy. Saline-treated PbA-infected mice showed increased
number of sequestered adherent leukocytes and platelets
in pial venules on day 6 of infection (Figure 2A,B). Treat-
ment with DPTA-NO significantly reduced the number
of both leukocytes and platelets in pial vessels.
DPTA-NO treatment prevents albumin leakage in pial
arterioles and venules
Mice with CM show breakdown of the blood-brain bar-
rier, as generally observed by whole brain leakage of
Evans blue dye [29]. Evaluation of albumin leakage in
individual vessels by intravital microscopy revealed that
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leakage occurred in both arterioles and venules and was
prevented by treatment with DPTA-NO (Figure 2C,D).
Adherent leukocytes and platelets, but not leakage,
co-localize
We asked whether vessel size would affect leukocyte/pla-
telet adherence and intensity of leakage in saline-treated
PbA-infected mice, and whether venules presenting
higher numbers of adherent leukocytes would also pre-
sent higher platelet adherence and more intense leakage.
Leukocyte (r2 = 0.21) and platelet (r2 = 0.15) adherence,
but not albumin leakage (r2 = 0.03), were significantly
correlated with increasing venular diameters. Vessels with
more leukocytes also presented more platelets, this corre-
lation being also present in DPTA-NO-treated mice
despite the lower numbers of adherent cells. Platelet
adherence (r2 = 0.49), but not leakage (r2 = 0.01), was
significantly correlated with leukocyte adherence in
venules. No correlation was found between leukocyte or
platelet adherence and leakage (r2 = 0.06).
Effect of exogenous NO on leukocyte and platelet
accumulation differs according to venular diameter
DPTA-NO treatment affected the distribution of adher-
ent leukocytes at different microvessel diameters. While
in saline-treated animals the number of adherent leuko-
cytes increased with increasing venular diameter, in
DPTA-NO-treated mice the distribution of adherent
leukocytes was relatively homogeneous in microvessels
of different diameters (Figure 3A,B). These results sug-
gest that DPTA-NO largely inhibited leukocyte accumu-


















































































Figure 1 Nitric oxide decreases cell adhesion molecule expression in the brain during Plasmodium berghei ANKA infection. Expression
levels of ICAM-1, VCAM-1, P-selectin and E-selectin in the brain of uninfected and PbA-infected saline-treated and DPTA-NO-treated mice (day 6
of infection). Expression levels were normalized in relation to GAPDH expression. Saline-treated mice showed increased expression of ICAM-1,
VCAM-1 and P-selectin, but not E-selectin. DPTA-NO treatment significantly decreased ICAM-1 and P-selectin, but not VCAM-1, expression.
*: p < 0.05; **: p < 0.01; ***: p < 0.001.
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Decrease in leukocyte accumulation by exogenous NO
affect vascular resistance
To analyze the effect of leukocyte accumulation on
venular resistance to blood flow, venules were categor-
ized in three groups based on diameter: 20-30 μm, 30-
40 μm and 40-50 μm. Figure 4A shows the mean num-
ber of leukocytes and platelets per category. In venules
of saline-treated PbA-infected mice, leukocyte accumu-
lation resulted in increased resistance to blood flow, par-
ticularly in the range of 20-40 μm in diameter (Figure
4B). Due to larger diameters the degree of leukocyte
accumulation in vessels 40-50 μm-diameter did not sub-
stantially affect vascular resistance. DPTA-NO treatment
had little effect upon leukocyte accumulation in smaller
venules (20-30 μm in diameter) and therefore its effect
on decreasing vascular resistance was felt only in vessels
in the 30-40 μm-diameter range. Because hydrostatic
pressure is lower in larger venules, the reduction of vas-
cular resistance in larger venules is expected to increase
venous return in DPTA-NO-treated mice.
Discussion
Murine cerebral malaria is associated with increased
expression of eCAMs as well as leukocyte and platelet
accumulation in brain vessels leading to microvascular
damage and BBB breakdown [8,30]. Here we show that
exogenous NO supplementation attenuated, although it
did not prevent, brain vascular inflammation (eCAM
expression, leukocyte and platelet accumulation) and
its consequences such as vascular leakage. We have
previously shown that exogenous NO supplementation
ameliorated pial blood flow, vasoconstriction and the
occurrence of brain hemorrhages [18]. Overall, these
results indicate that low NO bioavailability has a role in
the microvascular dysfunction observed during murine
CM [13] and that exogenous NO can help to protect the
vasculature, attenuating endothelial damage and dysfunc-
tion. The only partial effects of DPTA-NO treatment
on inflammatory markers and on brain hemodynamics
suggest that NO supplementation provides a subtle bene-























































































Figure 2 Nitric oxide decreases leukocyte and platelet adherence and vascular leakage during Plasmodium berghei ANKA infection.
Mean number of adherent leukocytes (A) and platelets (B) in pial venules, and albumin leakage in arterioles (C) and venules (D) of saline-treated
(n = 6) and DPTA-NO-treated (n = 6) PbA-infected mice on day 6 of infection, and in uninfected control mice (n = 5). A total of 6-8 venules and
4-6 arterioles were analyzed per mouse. Saline-treated mice showed increased number of adherent leukocytes and platelets, as well as increased
vascular permeability, and DPTA-NO treatment markedly inhibited adherence and leakage. **: p < 0.01; ***: p < 0.001; NS: non-significant.
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number of animals can be enough to prevent death by
CM, rather than an unmistakable modification of disease
history. In addition, the overlap between treated and
untreated mice in several of the measured parameters
might suggest that NO-mediated mechanisms other than
the ones reported here could be responsible for the clini-
cal effect.
Studies of eCAM expression in human and murine
CM consistently show an increased expression of
ICAM-1, whereas the results for other eCAMs are vari-
able. In cases of fatal human CM, the picture that
emerges is of marked increases in ICAM-1, significant
but less pronounced increases in VCAM-1 and E-selec-
tin and no changes in P-selectin expression in the brain
[31-33]. In murine CM, high expression of ICAM-1 in
the brain is consistently observed [12,34,35] and
VCAM-1 expression has been shown to be also mark-
edly increased in brain and retinal vessels [12,35].
P-selectin was shown to be increased whereas no change
in E-selectin was reported on day 6 of infection [12,36].
Similarly, in the present study, we found a marked
increase in ICAM-1 expression in the brain on day 6 of
infection, VCAM-1 and P-selectin had more modest
increases and E-selectin expression was not significantly
different in uninfected and saline-treated mice. ICAM-1,
indeed, seems to play a relevant role in CM, as not only
its expression in brain is consistently markedly
increased, but also ICAM-1 gene knockout mice are
protected from CM development [37,38]. The roles of
VCAM-1, E- and P-selectin are less clear. Increased
expression of E- and P-selectin seems to be less intense
in the brain as compared to other organs and tissues
during PbA infection and also sepsis [12,39]. Whether
the lower magnitude of expression of selectins in the
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Figure 3 Effect of DPTA-NO treatment on leukocyte and
platelet adherence during PbA infection. (A): Leukocyte and
platelet adherence significantly correlate with increasing venular
diameters in saline-treated (A) but not in DPTA-NO-treated (B) PbA-
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B
Figure 4 Effect of DPTA-NO treatment on venular resistance to
blood flow on day 6 of infection. Venules were categorized in
three brackets according to diameter: 20-30 μm, 30-40 μm and
40-50 μm. (A): number of adherent leukocytes and platelets per
category: accumulation of leukocytes and platelets increases in the
higher diameter brackets in saline-treated but not in DPTA-NO-
treated mice. (B): Venular resistance to blood flow is increased in all
brackets in saline-treated PbA-infected mice in relation to vessels
without inflammation (WI - dashed line), particularly in the 30-40
μm range (P < 0.05). DPTA-NO treatment has no effect on venular
resistance in smaller (20-30 μm) venules but significantly decreases
resistance in larger (30-40 μm) venules. Although the number of
leukocytes is higher in venules 40-50 μm in saline-treated PbA-
infected mice, the effect on resistance to blood flow is minor. Data
in (A) and (B) are the mean ± standard deviation.
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brain is relevant for CM development is debatable. P-
selectin gene knockout did not change leukocyte accu-
mulation in the brain during murine CM, and although
causing a short delay in mortality it did not prevent it
[36].
Low NO bioavailability plays a role in murine CM
pathogenesis [9] and it can help to explain the increased
expression of eCAMs in brain vessels with the conse-
quent rolling and adherence of leukocytes during PbA
infection. Indeed, impaired NO production by NO
synthase (NOS) inhibitors such as L-NAME, or by NOS
gene knockout, has been shown to increase eCAM
expression in vivo and in vitro [19-21,25]. Increased
eCAM expression as well as vascular inflammation and
platelet activation are also observed in hemolytic pathol-
ogies such as sickle cell crisis, in which cell-free hemo-
globin acts as a potent NO scavenger limiting NO
bioavailability [27]. Increased eCAM expression is fol-
lowed by increased leukocyte rolling and adherence [25],
and NO supplementation with NO donors can inhibit
eCAM expression and leukocyte migration [26,40]. Here
we show that exogenous NO indeed caused a significant
downregulation of ICAM-1 and P-selectin, but not
VCAM-1, expression in the brain of PbA-infected mice
and, therefore, this may help to explain the protective
effect of NO on murine CM. It is noteworthy, however,
that exogenous NO decreased but did not actually pre-
vent ICAM-1 expression, and did not significantly
decrease VCAM-1 expression in PbA-infected mice.
Accordingly, it decreased but did not prevent leukocyte
and platelet accumulation in the brain on day 6,
although it did prevent vascular leakage. While low NO
bioavailability is an important component of endothelial
dysfunction, it is not the sole cause of vascular inflam-
mation in murine CM, which is the result of a complex
cascade of events, including early activation of T cells
[41] and production and release of high levels of several
inflammatory cytokines [8]. The partial inhibitory effect
of NO supplementation on the inflammatory process
during PbA infection is in agreement with our previous
study showing that exogenous NO supplementation
with DPTA-NO attenuated but did not inhibit the brain
microcirculatory complications in PbA infection [18].
In saline-treated PbA-infected mice, the venular sites
with higher accumulation of leukocytes presented higher
platelet counts. Because there were also direct correla-
tions between the number of adherent leukocytes/plate-
lets and venular diameters, this finding indicates that
the differential quantitative accumulation was due basi-
cally to the larger available area for binding in larger
vessels rather than to eventual differential expression of
eCAMs in different vascular beds, although the latter
was not directly assessed and cannot be ruled out. This
is in accordance with previous findings by Sun and
colleagues regarding platelet adherence during murine
CM [42]. These results indicate that, during PbA infec-
tion, cerebral venules of different sizes in the range ana-
lyzed are similarly activated and similarly receptive to
leukocyte and platelet adherence. DPTA-NO treatment,
however, seems to differentially affect venules according
to their size, as it had little effect on leukocyte accumu-
lation in smaller (20-30 μm) venules and marked effect
in larger (30-50 μm) ones. This effect is important not
only in the sense that decreased inflammation may help
preserve vascular integrity, but also because it decreases
leukocyte-induced increases in vascular resistance, there-
fore increasing venous return and potentially improving
blood flow. In our previous study [18], DPTA-NO sus-
tained superior hemodynamics compared to saline,
which in part is due to reduced vascular resistance due
to geometrical and inflammatory changes. The results of
these studies strongly support the view that NO therapy
with a stable and long-acting molecule may constitute a
useful therapeutic approach to partially decrease recep-
tor-ligands interactions involved in CM cell adhesion
and related hemodynamic complications. This may be
true as well for mediators such as erythropoietin, which
enhances endothelium-dependent vasodilatation
mediated by NO in rodent cerebral vessels [43] and pre-
vents vascular inflammation [44] and has also been
shown to decrease inflammatory markers and partially
protect mice against CM development [45].
Several studies have shown that murine CM is asso-
ciated with BBB breakdown with consequent vascular
leakage [29,35]. Here we studied the vascular leakage at
the level of individual pial blood vessels and show that
arterioles and venules were similarly affected in PbA-
infected mice leading to increased albumin leakage to
the brain tissue. Because no correlation was found
between leakage and leukocyte/platelet adherence or
vessel diameters in venules, and because leakage
occurred in arterioles where leukocyte/platelet adher-
ence was minimal, these results indicate that the
endothelial dysfunction leading to increased permeability
in the brain vessels is not dependent on close contact
with inflammatory cells. In our study in no case the stu-
died sites presented evidence of vessel wall rupture,
which would lead to massive leakage and hemorrhage.
Therefore, although no correlation was found between
sites of leakage and of leukocyte/platelet accumulation,
we were not able to establish any relation between the
latter and more severe vascular damage. Inhibition of
NO production can result in increased vascular perme-
ability [46] and therefore the low NO bioavailability dur-
ing PbA infection can help to explain increased vascular
leakage. Exogenous NO treatment was indeed sufficient
to prevent vascular leakage in pial vessels. This is again
in accordance with our previous data showing marked
Zanini et al. Journal of Neuroinflammation 2011, 8:66
http://www.jneuroinflammation.com/content/8/1/66
Page 7 of 9
protection against brain hemorrhages provided by
DPTA-NO treatment, despite only partial effect on pial
hemodynamics [18].
In summary, exogenous NO supplementation signifi-
cantly decreases brain vascular inflammation during
PbA infection by decreasing the expression of eCAMs
and consequently decreasing recruitment of leukocytes
and platelets, which eventually results in decreased vas-
cular dysfunction and damage.
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